AbstractOncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly underst...

In a new study, published today in Cancer Discovery, the eDyNAmiC team, led by Paul Mischel at Stanford University, and collaborator Charlie Swanton at the Crick, integrated genomic and imaging data f...

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencie...

Researchers from the Francis Crick Institute, UCL, Gustave Roussy and Memorial Sloan Kettering Cancer Center (MSK), have discovered that expansion of mutant blood cells, a phenomenon linked to ageing,...

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencie...

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencie...

Opportunities for postdoctoral clinicians to consolidate their research experience.

Immune lymphocyte estimation from nucleotide sequencing (ImmuneLENS) infers B cell and T cell fractions from whole-genome sequencing data. Applied to the 100,000 Genomes Project datasets, circulating ...

Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of patients with lung adenocarcino...

A new test, developed by researchers from UCL Cancer Institute and the Francis Crick Institute, can better predict lung cancer survival at the point of diagnosis, which could inform treatment decision...

Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to detect circulating tumour DNA can predict lung cancer outcome in a Cancer Research UK-funded study.

Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to detect circulating tumour DNA can predict lung cancer outcome in a Cancer Research UK-funded study.